Mary Mehlig - Concepedia

Author

Mary Mehlig

Enzon Pharmaceuticals (United States)

Also Known As

M MEHLIG, M. Mehlig, Mary Mehlig

Publications

829

Citations

H-Index

Concepts

All Affiliations

Enzon Pharmaceuticals (United States)

About

Mary Mehlig is an author at Enzon Pharmaceuticals (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	492
2	Natural Sciences	2	2	331
3	Biomolecular Engineering	2	2	331
4	Engineering	1	1	118
5	Biochemistry	1	1	118

Mary Mehlig

Publications

827

Citations

H-Index

Page 1

	Year	Citations
Structure−Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation Amartya Basu, Karen Yang, Maoliang Wang, Bioconjugate Chemistry Ethylene GlycolImmunologyStructure−function EngineeringBiological TherapyTherapeutics	2006	213
Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model Puja Sapra, Hong Zhao, Mary Mehlig, Clinical Cancer Research	2008	165
Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation Kaiyong Yang, Anirban Basu, Ramesh Chintala, Protein Engineering Design and Selection EngineeringProtein AssemblyPeptide EngineeringImmunologyMolecular Biology	2003	118
Antitumor activity of poly(ethylene glycol)–camptothecin conjugate: The inhibition of tumor growth in vivo Deshan Yu, Ping Peng, S. Dharap, Journal of Controlled Release Tumor BiologyEthylene GlycolOncologyAntitumor ActivityPolymer-drug Conjugate	2005	116
Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C.II. Efficacy in ascites and solid tumors Yun H. Choe, Cheryl A. Conover, Dee Wu, Journal of Controlled Release NanomedicineEthylene GlycolDrug TargetingOncologySolid Tumors	2002	77
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects Puja Sapra, Patricia Kraft, Fabio Pastorino, Angiogenesis Cancer BiologyGliomaSustained InhibitionTumor BiologyAngiogenesis	2011	66
Engineering an Arginine Catabolizing Bioconjugate: Biochemical and Pharmacological Characterization of PEGylated Derivatives of Arginine Deiminase from <i>Mycoplasma arthritidis</i> Maoliang Wang, Amartya Basu, Thomas Palm, Bioconjugate Chemistry	2006	27
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma Puja Sapra, Patricia Kraft, Mary Mehlig, Haematologica	2009	25
Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy Hong Zhao, Ping Peng, Clifford Longley, Journal of Controlled Release Cell-based Drug DeliveryOncologyPharmacokinetic ProfileMedicineReleasable Peg-linkers	2006	20

Page 1